141 related articles for article (PubMed ID: 9796043)
1. A model to estimate the potential economic benefits of measles eradication for the United States.
Miller MA; Redd S; Hadler S; Hinman A
Vaccine; 1998 Dec; 16(20):1917-22. PubMed ID: 9796043
[TBL] [Abstract][Full Text] [Related]
2. A benefit-cost analysis of two-dose measles immunization in Canada.
Pelletier L; Chung P; Duclos P; Manga P; Scott J
Vaccine; 1998; 16(9-10):989-96. PubMed ID: 9682349
[TBL] [Abstract][Full Text] [Related]
3. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
[TBL] [Abstract][Full Text] [Related]
4. Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases.
Thompson KM; Badizadegan ND
Risk Anal; 2017 Jun; 37(6):1109-1131. PubMed ID: 28561947
[TBL] [Abstract][Full Text] [Related]
5. Future savings from measles eradication in industrialized countries.
Carabin H; Edmunds WJ
J Infect Dis; 2003 May; 187 Suppl 1():S29-35. PubMed ID: 12721889
[TBL] [Abstract][Full Text] [Related]
6. From the Centers for Disease Control and Prevention. Measles--United States, 1996, and the interruption of indigenous transmission.
JAMA; 1997 May; 277(17):1345-6. PubMed ID: 9134928
[No Abstract] [Full Text] [Related]
7. Benefits, risks and costs of immunization for measles, mumps and rubella.
White CC; Koplan JP; Orenstein WA
Am J Public Health; 1985 Jul; 75(7):739-44. PubMed ID: 3923849
[TBL] [Abstract][Full Text] [Related]
8. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
Heath TC; Burgess MA; O'Brien ED
Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551
[No Abstract] [Full Text] [Related]
9. Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program.
Babigumira JB; Levin A; Burgess C; Garrison LP; Bauch CT; Braka F; Mbabazi WB; Nabyonga JO; Simons E; Dabbagh A
J Infect Dis; 2011 Jul; 204 Suppl 1():S116-23. PubMed ID: 21666152
[TBL] [Abstract][Full Text] [Related]
10. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
[TBL] [Abstract][Full Text] [Related]
11. Measles-mumps-rubella immunization of susceptible hospital employees during a community measles outbreak: cost-effectiveness and protective efficacy.
Stover BH; Adams G; Kuebler CA; Cost KM; Rabalais GP
Infect Control Hosp Epidemiol; 1994 Jan; 15(1):18-21. PubMed ID: 8133004
[TBL] [Abstract][Full Text] [Related]
12. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
[TBL] [Abstract][Full Text] [Related]
13. Catch-up immunization programs will eliminate measles threat for most schoolchildren.
Rafuse J
CMAJ; 1996 May; 154(10):1567-8. PubMed ID: 8625011
[TBL] [Abstract][Full Text] [Related]
14. Measles--United States, 1996, and the interruption of indigenous transmission.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1997 Mar; 46(11):242-6. PubMed ID: 9082179
[TBL] [Abstract][Full Text] [Related]
15. Global measles elimination efforts: the significance of measles elimination in the United States.
Strebel PM; Henao-Restrepo AM; Hoekstra E; Olive JM; Papania MJ; Cochi SL
J Infect Dis; 2004 May; 189 Suppl 1():S251-7. PubMed ID: 15106119
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of prevaccination screening of health care workers for immunity to measles, rubella and mumps.
Ferson MJ; Robertson PW; Whybin LR
Med J Aust; 1994 Apr; 160(8):478-82. PubMed ID: 8170422
[TBL] [Abstract][Full Text] [Related]
18. [Economic evaluation on different two-dose-vaccination-strategies related to Measles, Mumps and Rubella Combined Attenuated Live Vaccine].
He HQ; Zhang B; Yan R; Li Q; Fu J; Tang XW; Zhou Y; Deng X; Xie SY
Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Aug; 37(8):1121-6. PubMed ID: 27539345
[TBL] [Abstract][Full Text] [Related]
19. Measles eradication: recommendations from a meeting cosponsored by the World Health Organization, the Pan American Health Organization, and CDC.
MMWR Recomm Rep; 1997 Jun; 46(RR-11):1-20. PubMed ID: 9213745
[TBL] [Abstract][Full Text] [Related]
20. Measles control in developing and developed countries: the case for a two-dose policy.
Tulchinsky TH; Ginsberg GM; Abed Y; Angeles MT; Akukwe C; Bonn J
Bull World Health Organ; 1993; 71(1):93-103. PubMed ID: 8440043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
